Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Increased Cancer Death Linked to Radioactive Iodine Therapy

Publish date:: August 1, 2019

Key clinical point: Radioactive iodine therapy linked to increased risk of solid cancer death.

Major finding: Around 8% of solid cancer deaths among patients who have undergone radioactive iodine therapy might be attributed to the radiation.

Study details: Longitudinal cohort study in 18,805 individuals with hyperthyroidism.

Disclosures: The study was funded by the National Cancer Institute. One author declared membership of a consortium supported by the pharmaceutical sector.

Citation:

Kitahara C et al. JAMA Internal Medicine 2019, July 1. DOI:10.1001/jamainternmed.2019.0981.

This Week's Must Reads

Phase II Trial of DNA Vaccine Encoding PAP in Patients with PCa ,

Utilization of Surgery for Post-prostatectomy Incontinence,

Claims Analysis of Advanced PCa Treatment Costs and Resource Use,

Testosterone Therapy Doesn't Increase Prostate Cancer Risk,

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced PCa,

Must Reads in Breast Cancer

Increased Cancer Death Linked to Radioactive Iodine Therapy,

Bioimpedance Spectroscopy May Better Identify Lymphedema Progression,

Stereotactic Radiotherapy System Approved For BC, FDA news release; 2017 Dec 22

Perjeta Approved for Certain Type of Early BC, Genentech news release; 2017 Dec 20

Cochrane on Bisphosphonates for Breast Cancer, Cochrane; 2017 Oct 30; O'Carrigan, Wong, et al